Visual Abstract - Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction: 10.1016/j.jacbts.2016.09.004

• The inflammatory enzyme MPO is a potential therapeutic target in cardiovascular diseases.

• PF-1355 is an orally bioavailable mechanism-based inhibitor of MPO enzymatic activity. PF-1355 treatment successfully inhibited MPO in mouse models of myocardial infarction and ischemia reperfusion injury.

• Short duration oral drug treatment for 7 days attenuated inflammation and cardiac dilation during early infarct healing. However, MPO-containing cells persisted beyond 7 days.

• Prolonged 21-day treatment improved ejection fraction (∼44%) and decreased end-diastolic volume (∼53%) and left ventricular mass (∼33%) compared with untreated control subjects.

• Better therapeutic effect was also achieved when treatment was started early (at 1 h) after the initial ischemic insult.